Skip to main content
Erschienen in: Tumor Biology 2/2011

01.04.2011 | Research Article

A critical role of Sp1 transcription factor in regulating the human Ki-67 gene expression

verfasst von: Hui Tian, Guo-Wei Qian, Wang Li, Fei-Fei Chen, Jie-Hui Di, Bao-Fu Zhang, Dong-Sheng Pei, Ping Ma, Jun-Nian Zheng

Erschienen in: Tumor Biology | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Ki-67 plays a crucial role in cell proliferation as well as maintenance or regulation of cell division. The mechanism governing the Ki-67 gene expression remains unknown. Thus, we cloned the core promoter of the human Ki-67 gene and further investigated its transcriptional regulation. The putative Sp1 binding sites were confirmed by electrophoretic mobility shift assay together with an anti-Sp1 antibody-mediated supershift assay. Deletion mutagenesis and firefly luciferase reporter gene assay demonstrated the essential contribution of Sp1 on transcriptional activation of the Ki-67 gene. In this study, we first confirm that there are three Sp1 binding sites in the Ki-67 core promoter. Two Sp1 sites (one at position −159 to −145 nt and the other at position −14 to +12 nt) are mainly involved in transcriptional regulation of the Ki-67 gene. Overexpression of Sp1 can enhance the Ki-67 promoter activity. However, down-regulation of Sp1 expression using siRNA-Sp1 and mithramycin effectively inhibits the Ki-67 gene transcription. Our results suggest that Sp1 is essential for basal promoter activity of the human Ki-67 gene. Inhibition of the Ki-67 transcriptional activity through abolishment of Sp1 may provide the useful prospect for gene therapy.
Literatur
1.
Zurück zum Zitat Duchrow M, Schlueter C, Wohlenberg C, Flad HD, Gerdes J. Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki-67. Cell Prolif. 1996;29:1–12.CrossRefPubMed Duchrow M, Schlueter C, Wohlenberg C, Flad HD, Gerdes J. Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki-67. Cell Prolif. 1996;29:1–12.CrossRefPubMed
2.
Zurück zum Zitat MacCallum DE, Hall PA. Biochemical characterization of pKi67 with the identification of a mitotic-specific form associated with hyperphosphorylation and altered DNA binding. Exp Cell Res. 1999;252:186–98.CrossRefPubMed MacCallum DE, Hall PA. Biochemical characterization of pKi67 with the identification of a mitotic-specific form associated with hyperphosphorylation and altered DNA binding. Exp Cell Res. 1999;252:186–98.CrossRefPubMed
3.
Zurück zum Zitat Schlüter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, et al. The cell proliferation associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol. 1993;123:513–22.CrossRefPubMed Schlüter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, et al. The cell proliferation associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol. 1993;123:513–22.CrossRefPubMed
4.
Zurück zum Zitat MaCallum DE, Hall PA. Biochemical characterization of pKi-67 with the identification of a mitotic-specific form association with hyperphosphorylation and altered DNA binding. Exp Cell Res. 1991;52:186–98. MaCallum DE, Hall PA. Biochemical characterization of pKi-67 with the identification of a mitotic-specific form association with hyperphosphorylation and altered DNA binding. Exp Cell Res. 1991;52:186–98.
5.
Zurück zum Zitat Kausch I, Jiang H, Ewerdwalbesloh N, Doehn C, Kruger S, Sczakiel G, et al. Inhibition of Ki-67 in a renal cell carcinoma severe combined immunodeficiency disease mouse model is associated with induction of apoptosis and tumour growth inhibition. BJU Int. 2005;95:416–20.CrossRefPubMed Kausch I, Jiang H, Ewerdwalbesloh N, Doehn C, Kruger S, Sczakiel G, et al. Inhibition of Ki-67 in a renal cell carcinoma severe combined immunodeficiency disease mouse model is associated with induction of apoptosis and tumour growth inhibition. BJU Int. 2005;95:416–20.CrossRefPubMed
6.
Zurück zum Zitat Dynan WS, Tjian R. Isolation of transcription factors that discriminate between different promoters recongnized by RNA polymerase II. Cell. 1983;32:669–80.CrossRefPubMed Dynan WS, Tjian R. Isolation of transcription factors that discriminate between different promoters recongnized by RNA polymerase II. Cell. 1983;32:669–80.CrossRefPubMed
7.
Zurück zum Zitat Dynan WS, Tjian R. The promoter-specific transcription factor Sp1 binds to upstream sequences in the SV40 early promoter. Cell. 1983;35:79–87.CrossRefPubMed Dynan WS, Tjian R. The promoter-specific transcription factor Sp1 binds to upstream sequences in the SV40 early promoter. Cell. 1983;35:79–87.CrossRefPubMed
9.
Zurück zum Zitat Kadonaga JT, Carner KR, Masiarz FR, Tjian R. Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell. 1987;51:1079–90.CrossRefPubMed Kadonaga JT, Carner KR, Masiarz FR, Tjian R. Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell. 1987;51:1079–90.CrossRefPubMed
10.
Zurück zum Zitat Endl E, Gerdes J. Post-translational modifications of the Ki-67 protein coincide with two major check points during mitosis. J Cell Physiol. 2000;182:371–80.CrossRefPubMed Endl E, Gerdes J. Post-translational modifications of the Ki-67 protein coincide with two major check points during mitosis. J Cell Physiol. 2000;182:371–80.CrossRefPubMed
11.
Zurück zum Zitat Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.CrossRefPubMed Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.CrossRefPubMed
12.
Zurück zum Zitat Takagi M, Matsuoka Y, Kurihara T, Yoneda Y. Chmadrin: a novel Ki-67 antigen-related perichromosomal protein possibly implicated in higher order chromatin structure. J Cell Sci. 1999;112:2463–72.PubMed Takagi M, Matsuoka Y, Kurihara T, Yoneda Y. Chmadrin: a novel Ki-67 antigen-related perichromosomal protein possibly implicated in higher order chromatin structure. J Cell Sci. 1999;112:2463–72.PubMed
13.
Zurück zum Zitat Yang X, Su K, Roos MD, Chang Q, Paterson AJ, Kudlow JE. O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability. Proc Natl Acad Sci. 2001;98:6611–6.CrossRefPubMed Yang X, Su K, Roos MD, Chang Q, Paterson AJ, Kudlow JE. O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability. Proc Natl Acad Sci. 2001;98:6611–6.CrossRefPubMed
14.
Zurück zum Zitat Su K, Roos MD, Yang X, Han I, Paterson AJ, Kudlow JE. An N-terminal region of Sp1 targets its proteasome dependent degradation in vitro. J Biol Chem. 1999;274:15194–202.CrossRefPubMed Su K, Roos MD, Yang X, Han I, Paterson AJ, Kudlow JE. An N-terminal region of Sp1 targets its proteasome dependent degradation in vitro. J Biol Chem. 1999;274:15194–202.CrossRefPubMed
15.
Zurück zum Zitat Safe S, Abdelrahim M. Sp transcription factor family and its role in cancer. Eur J Cancer. 2005;41:2438–48.CrossRefPubMed Safe S, Abdelrahim M. Sp transcription factor family and its role in cancer. Eur J Cancer. 2005;41:2438–48.CrossRefPubMed
16.
Zurück zum Zitat Safe S, Kim K. Nuclear receptor-mediated transactivation through interaction with Sp proteins. Prog Nucleic Acid Res Mol Biol. 2004;77:1–36.CrossRefPubMed Safe S, Kim K. Nuclear receptor-mediated transactivation through interaction with Sp proteins. Prog Nucleic Acid Res Mol Biol. 2004;77:1–36.CrossRefPubMed
17.
Zurück zum Zitat Bouwman P, Philipsen S. Regulation of the activity of Sp1-related transcription factors. Mol Cell Endocrinol. 2002;195:27–38.CrossRefPubMed Bouwman P, Philipsen S. Regulation of the activity of Sp1-related transcription factors. Mol Cell Endocrinol. 2002;195:27–38.CrossRefPubMed
18.
Zurück zum Zitat Li L, He S, Sun JM, Davie JR. Gene regulation by Sp1 and Sp3. Biochem Cell Biol. 2004;82:460–71.CrossRefPubMed Li L, He S, Sun JM, Davie JR. Gene regulation by Sp1 and Sp3. Biochem Cell Biol. 2004;82:460–71.CrossRefPubMed
19.
Zurück zum Zitat Barth N, Langmann T, Scholmerich J, Schmitz G, Schaffler A. Identification of regulatory elements in the human adipose most abundant gene transcript-1 (apM-1) promoter: role of SP1/SP3 and TNF-alpha as regulatory pathways. Diabetologia. 2002;45:1425–33.PubMed Barth N, Langmann T, Scholmerich J, Schmitz G, Schaffler A. Identification of regulatory elements in the human adipose most abundant gene transcript-1 (apM-1) promoter: role of SP1/SP3 and TNF-alpha as regulatory pathways. Diabetologia. 2002;45:1425–33.PubMed
20.
Zurück zum Zitat Wang LW, Wei DY, Huang SY, Peng ZH, Le XD, Wu TT, et al. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res. 2003;9:6371–80.PubMed Wang LW, Wei DY, Huang SY, Peng ZH, Le XD, Wu TT, et al. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res. 2003;9:6371–80.PubMed
21.
Zurück zum Zitat Shi Q, Le XD, Abbruzzese JL, Peng ZH, Qian CN, Tang HM, et al. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res. 2001;61:4143–54.PubMed Shi Q, Le XD, Abbruzzese JL, Peng ZH, Qian CN, Tang HM, et al. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res. 2001;61:4143–54.PubMed
22.
Zurück zum Zitat Chiefari E, Brunetti A, Arturi F, Bidart JM, Russo D, Schlumberger M, et al. Increased expression of AP2 and Sp1 transcription factors in human thyroid tumours: a role in NIS expression regulation. BMC Cancer. 2002;2:35.CrossRefPubMed Chiefari E, Brunetti A, Arturi F, Bidart JM, Russo D, Schlumberger M, et al. Increased expression of AP2 and Sp1 transcription factors in human thyroid tumours: a role in NIS expression regulation. BMC Cancer. 2002;2:35.CrossRefPubMed
23.
Zurück zum Zitat Hosoi Y, Watanabe T, Nakagawa K, Matsumoto Y, Enomoto A, Morita A, et al. Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer. Int J Oncol. 2004;25:461–8.PubMed Hosoi Y, Watanabe T, Nakagawa K, Matsumoto Y, Enomoto A, Morita A, et al. Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer. Int J Oncol. 2004;25:461–8.PubMed
24.
Zurück zum Zitat Jang SI, Steinert PM. Loricrin expression in cultured human keratinocytes is controlled by a complex interplay between transcription factors of the Sp1, CREB, AP1, and AP2 families. J Biol Chem. 2002;277:42268–79.CrossRefPubMed Jang SI, Steinert PM. Loricrin expression in cultured human keratinocytes is controlled by a complex interplay between transcription factors of the Sp1, CREB, AP1, and AP2 families. J Biol Chem. 2002;277:42268–79.CrossRefPubMed
25.
Zurück zum Zitat Suzuki T, Kimura A, Nagai R, Horikoshi M. Regulation of interaction of the acetyltransferase region of p300 and the DNA-binding domain of Sp1 on and through DNA binding. Genes Cells. 2000;5:29–41.CrossRefPubMed Suzuki T, Kimura A, Nagai R, Horikoshi M. Regulation of interaction of the acetyltransferase region of p300 and the DNA-binding domain of Sp1 on and through DNA binding. Genes Cells. 2000;5:29–41.CrossRefPubMed
Metadaten
Titel
A critical role of Sp1 transcription factor in regulating the human Ki-67 gene expression
verfasst von
Hui Tian
Guo-Wei Qian
Wang Li
Fei-Fei Chen
Jie-Hui Di
Bao-Fu Zhang
Dong-Sheng Pei
Ping Ma
Jun-Nian Zheng
Publikationsdatum
01.04.2011
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 2/2011
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-010-0119-4

Weitere Artikel der Ausgabe 2/2011

Tumor Biology 2/2011 Zur Ausgabe

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.